Ratings Ipca Laboratories Limited

Equities

IPCALAB

INE571A01038

Delayed NSE India S.E. Other stock markets 01:16:54 2024-05-03 am EDT			5-day change	1st Jan Change
1,353 ^INR	+0.18%		+2.34%	+21.72%

Mar. 29	Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director	CI
Mar. 29	Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

With an expected P/E ratio at 54.79 and 35.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 4.66 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
For the last few months, analysts have been revising downwards their earnings forecast.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
IPCA LABORATORIES LIMITED	+21.72%	4.11B	C+
ELI LILLY AND COMPANY	+29.68%	681B	C+
NOVO NORDISK A/S	+25.07%	556B	B
JOHNSON & JOHNSON	-4.35%	361B	C+
MERCK & CO., INC.	+17.65%	325B	B-
ABBVIE INC.	+3.77%	285B	C+
ASTRAZENECA PLC	+14.68%	235B	B+
NOVARTIS AG	+4.71%	199B	B-
ROCHE HOLDING AG	-12.43%	189B	A+
PFIZER, INC.	-3.79%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes